Home>Topics>>Vivus Vs. Citron, Buy Vivus

Vivus Vs. Citron, Buy Vivus

Healthcare Sector and Stocks Analysis from Seeking Alpha

Fri, 20 Jul 2012

By Rx Stocks : On Thursday, July 19, 2012, word spread of concerns raised by Citron Inc ( CTNI.PK ) that there are patent issues with Qsymia and that generics may compete with Qsymia. Vivus, Inc. ( VVUS ) traded down about $3 per share and some attribute the drop to the concerns raised by Citron. ...

Related Videos

  1. Dividend Investors: Check Into Energy Stocks

    Mon, 23 Jul 2012

    Recent underperformance has made energy a more interesting sector for dividend investors, says Morningstar's Josh Peters, who recommends this undervalued, utility-like energy name that has strong dividend growth prospects.

  2. That Good Dividend Yield Now Might Not Look So Good Later

    Mon, 23 Jul 2012

    Although the economy needs to improve before the Fed raises key rates, some dividend payers might act as good hedges amid higher rates, while others have something to lose, says Morningstar's Josh Peters.

  3. Pharma Looking Defensive Again

    Thu, 5 Jul 2012

    Pharmaceutical firms have adapted to their patent cliffs better than investors expected, and solid pricing power and improving pipelines are allowing them to push through macro headwinds.

  4. Linsanity a Slam Dunk for This Fund

    Tue, 24 Jul 2012

    Ariel's David Maley discusses how he finds names for his deep-value strategy and the benefits of investing in a certain sports-related firm.

Content Partners